Profund Advisors LLC Buys 25,568 Shares of CG Oncology, Inc. $CGON

Profund Advisors LLC grew its stake in CG Oncology, Inc. (NASDAQ:CGON) by 185.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,319 shares of the company’s stock after buying an additional 25,568 shares during the quarter. Profund Advisors LLC’s holdings in CG Oncology were worth $1,633,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Whittier Trust Co. of Nevada Inc. bought a new stake in CG Oncology in the 4th quarter valued at $27,000. Strengthening Families & Communities LLC bought a new position in CG Oncology during the 3rd quarter worth about $40,000. Comerica Bank raised its stake in shares of CG Oncology by 100.4% in the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of CG Oncology by 33.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after purchasing an additional 972 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of CG Oncology by 159.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock valued at $182,000 after purchasing an additional 4,288 shares in the last quarter. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at CG Oncology

In other news, Director James Mulay sold 15,600 shares of the company’s stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the sale, the director owned 15,600 shares in the company, valued at $1,138,956. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 4.80% of the stock is owned by company insiders.

CG Oncology Price Performance

Shares of NASDAQ CGON opened at $64.76 on Thursday. The business has a 50-day moving average of $67.20 and a 200-day moving average of $54.46. The stock has a market capitalization of $5.71 billion, a price-to-earnings ratio of -27.79 and a beta of 0.41. CG Oncology, Inc. has a fifty-two week low of $23.65 and a fifty-two week high of $75.50.

CG Oncology (NASDAQ:CGON) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The company had revenue of $1.08 million during the quarter, compared to analyst estimates of $0.45 million. On average, sell-side analysts expect that CG Oncology, Inc. will post -2.89 EPS for the current year.

Analyst Ratings Changes

CGON has been the subject of several recent research reports. Wall Street Zen cut CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. JPMorgan Chase & Co. lifted their target price on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of CG Oncology in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research report on Monday, April 20th. Finally, Wedbush raised their price target on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $81.73.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.